Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center

Archivos de la Sociedad Espanola de Oftalmologia Pub Date : 2025-04-01 DOI:10.1016/j.oftale.2025.03.009

P.D. Lara-Barrera, J.L. Tovilla-Canales, O. Olvera-Morales, E.G. Castillo-Pérez, Á. Nava-Castañeda

{"title":"Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center","authors":"P.D. Lara-Barrera, J.L. Tovilla-Canales, O. Olvera-Morales, E.G. Castillo-Pérez, Á. Nava-Castañeda","doi":"10.1016/j.oftale.2025.03.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objective</h3><div>Blepharospasm is characterized by involuntary, sustained spasms of the orbicularis oculi, corrugator, and procerus muscles. Hemifacial spasm (HFS) is characterized by the involuntary tonic-clonic contraction of the muscles of a hemiface. The main role of botulinum toxin type A (BoNT-A) in the treatment of blepharospasm and HFS is recognized by guidelines around the world. In this study, we evaluated the applicability of botulinum toxin type A in patients with periocular hyperkinetic disorders at the Instituto de Oftalmología Fundación Conde de Valenciana, so that we can share the Mexican experience with the international evidence.</div></div><div><h3>Materials and methods</h3><div>The clinical records of patients diagnosed with facial hyperkinetic disorders treated with botulinum toxin type A (BoNT-A) that were treated from January 2015 to September 2021 were analyzed.</div></div><div><h3>Results</h3><div>A total of 140 records of patients diagnosed with facial hyperkinetic disorder and treated with BoNT-A were analyzed. Facial hyperkinetic disorders that occurred included 5 (3.6%) patients with orbicularis oculi myokymia, 72 (51.4%) with blepharospasm, 62 (44.3%) with hemifacial spasm, and 1 (0.7%) with Meige syndrome. One hundred and twenty patients (85.7%) reported remission of initial symptoms after BoNT-A therapy during the period covered by this study.</div></div><div><h3>Conclusions</h3><div>Botulinum toxin type A is effective and safe as a treatment for facial hyperkinetic disorders in the Mexican population.</div></div>","PeriodicalId":93886,"journal":{"name":"Archivos de la Sociedad Espanola de Oftalmologia","volume":"100 4","pages":"Pages 191-196"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de la Sociedad Espanola de Oftalmologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173579425000350","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective

Blepharospasm is characterized by involuntary, sustained spasms of the orbicularis oculi, corrugator, and procerus muscles. Hemifacial spasm (HFS) is characterized by the involuntary tonic-clonic contraction of the muscles of a hemiface. The main role of botulinum toxin type A (BoNT-A) in the treatment of blepharospasm and HFS is recognized by guidelines around the world. In this study, we evaluated the applicability of botulinum toxin type A in patients with periocular hyperkinetic disorders at the Instituto de Oftalmología Fundación Conde de Valenciana, so that we can share the Mexican experience with the international evidence.

Materials and methods

The clinical records of patients diagnosed with facial hyperkinetic disorders treated with botulinum toxin type A (BoNT-A) that were treated from January 2015 to September 2021 were analyzed.

Results

A total of 140 records of patients diagnosed with facial hyperkinetic disorder and treated with BoNT-A were analyzed. Facial hyperkinetic disorders that occurred included 5 (3.6%) patients with orbicularis oculi myokymia, 72 (51.4%) with blepharospasm, 62 (44.3%) with hemifacial spasm, and 1 (0.7%) with Meige syndrome. One hundred and twenty patients (85.7%) reported remission of initial symptoms after BoNT-A therapy during the period covered by this study.

Conclusions

Botulinum toxin type A is effective and safe as a treatment for facial hyperkinetic disorders in the Mexican population.

查看原文本刊更多论文

在墨西哥眼科中心应用A型肉毒杆菌毒素治疗面部多动障碍的经验。

背景和目的：眼睑痉挛的特征是眼轮匝肌、瓦楞纸肌和降肌的不自主、持续痉挛。面肌痉挛（HFS）的特点是半面部肌肉的不自主强直阵挛性收缩。A型肉毒毒素（BoNT-A）在眼睑痉挛和HFS治疗中的主要作用已被世界各地的指南所认可。在本研究中，我们在Oftalmología Fundación Conde de Valenciana研究所评估A型肉毒杆菌毒素在眼周运动障碍患者中的适用性，以便与国际证据分享墨西哥的经验。材料与方法：分析2015年1月至2021年9月以A型肉毒毒素（BoNT-A）治疗的面部多动障碍患者的临床记录。结果：对140例诊断为面部多动障碍并经BoNT-A治疗的患者进行分析。发生的面部多动障碍包括眼轮轴肌肌肌无力5例（3.6%），眼睑痉挛72例（51.4%），面肌痉挛62例（44.3%），梅格综合征1例（0.7%）。120例患者（85.7%）报告在本研究期间BoNT-A治疗后初始症状缓解。结论：A型肉毒毒素作为一种治疗墨西哥人群面部多动障碍的有效和安全的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archivos de la Sociedad Espanola de Oftalmologia

自引率

0.00%

发文量